Claris Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Claris Advisors’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-278	Closed	-$14.4K	–	215
2024 Q3	$14.4K	Buy	+278	New	+$13K	0.01%	201

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Claris Advisors's BMY Position: Q4 2024 in Review

Claris Advisors sold out of Bristol-Myers Squibb (BMY) in Q4 2024, closing a stake of 278 shares — an estimated $14.4K sold.

Claris Advisors first reported a position in BMY in Q3 2024 and held it in 1 quarter. The position peaked at $14.4K in Q3 2024. 2,486 funds tracked by Wall St. Rank hold BMY as of Q4 2024.

Claris Advisors reported no remaining Bristol-Myers Squibb position as of Q4 2024 after selling out during the quarter.
Claris Advisors sold 278 Bristol-Myers Squibb shares in Q4 2024, an estimated $14.4K.
Claris Advisors first reported a position in Bristol-Myers Squibb in Q3 2024 and held it in 1 quarter.
Claris Advisors's Bristol-Myers Squibb position peaked at $14.4K in Q3 2024.
2,486 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2024.

Based on Claris Advisors's 13F filing for Q4 2024, filed 7 Feb 2025.